New pill aims to ease schizophrenia psychosis
NCT ID NCT05227703
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested two doses of a new drug called emraclidine (CVL-231) in 391 adults with schizophrenia who were having a sudden worsening of psychotic symptoms. Participants took the drug or a placebo daily for 6 weeks. The main goal was to see if the drug reduced symptoms like hallucinations and delusions better than a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Emraclidine (CVL-231)
What this could lead to
If it works, this could point toward a new treatment option for acute psychotic episodes in schizophrenia.
What could go wrong
This is a Phase 2 trial, so results are still early. The drug may not prove effective or could have side effects. It is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlanta, Georgia
Atlanta, Georgia, 30331-2012, United States
-
Austin, Texas
Austin, Texas, 78754-5122, United States
-
Bellflower, California
Bellflower, California, 90706-7079, United States
-
Bentonville, Arkansas
Bentonville, Arkansas, 72712-3873, United States
-
Berlin, New Jersey
Berlin, New Jersey, 08009, United States
-
Budapest, Budapest
Budapest, 1083, Hungary
-
Burgas, Burgas
Burgas, 8000, Bulgaria
-
Charlotte, North Carolina
Charlotte, North Carolina, 28211-4849, United States
-
Chicago, Illinois
Chicago, Illinois, 60640-5017, United States
-
Chicago, Illinois
Chicago, Illinois, 60641, United States
-
Győr, Győr-Moson-Sopron
Győr, Győr-Moson-Sopron, 9024, Hungary
-
Homestead, Florida
Homestead, Florida, 33032-8187, United States
-
Kalocsa, Bács-Kiskun
Kalocsa, Bács-Kiskun county, 6300, Hungary
-
La Habra, California
La Habra, California, 90631-3842, United States
-
Marlton, New Jersey
Marlton, New Jersey, 08053, United States
-
Miami Lakes, Florida
Miami Lakes, Florida, 33016-1553, United States
-
Miami Springs, Florida
Miami Springs, Florida, 33166-7225, United States
-
Miami, Florida
Miami, Florida, 33122-1335, United States
-
New Haven, Connecticut
New Haven, Connecticut, 06519-1109, United States
-
Pleven, Pleven
Pleven, 5800, Bulgaria
-
San Diego, California
San Diego, California, 92103-2209, United States
-
Savannah, Georgia
Savannah, Georgia, 31405-5701, United States
-
Sherman Oaks, California
Sherman Oaks, California, 91403-1747, United States
-
Sofia, Sofia
Sofia, 1282, Bulgaria
-
Sofia, Sofia-Grad
Sofia, Sofia-Grad, 1431, Bulgaria
-
Torrance, California
Torrance, California, 90504-4432, United States